BioCentury
ARTICLE | Clinical News

Galeterone: Phase III started

July 20, 2015 7:00 AM UTC

Tokai began the open-label, international Phase III ARMOR3-SV trial to compare 2,550 mg oral galeterone once daily vs. once-daily oral Xtandi enzalutamide in 148 treatment-naive patients whose tumors...